New cell therapy targets deadly belly fluid in Late-Stage cancer

NCT ID NCT07561437

Recruiting now Disease control Sponsor: Base Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen May 02, 2026 · Last updated May 12, 2026 · Updated 2 times

Summary

This early-phase study tests an experimental cell therapy called NK521 in 18 adults with advanced solid tumors (like liver, stomach, or ovarian cancer) that have not responded to at least two prior treatments and have caused malignant ascites—a painful buildup of fluid in the belly. Participants receive NK521 either through a vein or directly into the belly, once a week for two 3-week cycles. The main goals are to check safety and find the best dose, while also seeing if it can shrink tumors or reduce the need for fluid drainage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 010, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS